Secondary Progressive Multiple Sclerosis (SPMS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

  • Published Date : September 10, 2026
  • Updated On : November 6, 2026
  • Pages : 53

Secondary Progressive Multiple Sclerosis Unmet Needs and TPP Insights

Thelansis’s “Secondary Progressive Multiple Sclerosis (SPMS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Secondary Progressive Multiple Sclerosis Overview

Secondary progressive multiple sclerosis (SPMS) is a phase of MS in which disability gradually worsens after an initial relapsing-remitting course, with or without ongoing relapses. Persistent inflammation within the central nervous system, neuroaxonal loss and microglial activity contribute to progression. Symptoms include worsening mobility, spasticity, fatigue, sensory changes and cognitive difficulty. Management combines rehabilitation and symptom control with disease-modifying therapy when inflammatory activity persists. Siponimod is approved for active SPMS; other relapsing-MS therapies may be considered according to disease activity and local guidance. For non-relapsing SPMS, tolebrutinib (Cenrifki) was authorised in the EU in June 2026 and Australia in May 2026, but the FDA issued a complete response letter in December 2025, citing unresolved serious liver-injury risk. No treatment reverses established disability; preserving function and slowing progression remain major needs.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
    • Pipeline analysis
    • Target patients for emerging therapies
    • Key companies
    • Key mechanism of actions
    • Launch date estimates, etc.
  • Clinical trial landscape analysis
    • Target patient segments
    • Trial endpoints
    • Trial design
    • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
    • Performance of key current therapies
    • Top areas of unmet needs
    • Opportunity sizing for key unmet needs
  • Target Product Profiles
    • Attributes and levels
    • Physician likelihood of prescribing
    • Expected patient shares
  • KOL insights on key emerging therapies
    • Level of awareness
    • Expected use / line of therapy
    • Extent to fulfil key unmet needs
    • KOL quotes
 

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
    • Key therapies vs. focused patient segment
    • Key attributes and benefits
    • Futures treatment landscape
    • Current challenges
    • Unmet needs
  • Emerging therapies
    • Key therapies vs. focused patient segment
    • Key attributes and benefits
    • Futures treatment landscape
    • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)

Frequently asked questions